Lv4
490 积分 2025-03-07 加入
Disproportionate Right Ventricular Dysfunction and Poor Survival in Group 3 Pulmonary Hypertension
1个月前
已完结
Breakthroughs in our molecular understanding of therapeutic targets for pulmonary hypertension
1个月前
已完结
("Pulmonary Hypertension"[Mesh] OR "pulmonary hypertension" OR "pulmonary arterial hypertension" OR PAH) AND ("Metabolomics"[Mesh] OR metabolomic* OR metabolic profiling OR metabolic signature OR metabolite* OR metabolome)
1个月前
已关闭
Pulmonary hypertension: the unaddressed global health burden
1个月前
已完结
Pulmonary hypertension
1个月前
已完结
Distinct plasma proteome in severe pulmonary hypertension associated with chronic lung disease
1个月前
已完结
A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension
2个月前
已完结
Diffusing Capacity Is an Independent Predictor of Outcomes in Pulmonary Hypertension Associated With COPD
2个月前
已完结
TAPSE/sPAP Ratio to Improve Risk Assessment in Pulmonary Arterial Hypertension
4个月前
已完结
Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in Pulmonary Hypertension in Interstitial Lung Disease: A PVRI GoDeep Meta-Registry Analysis
5个月前
已完结
皖公网安备34019202002308
